Últimas noticias sobre Ernexa Therapeutics (NASDAQ:ERNA) Bolsa

Eterna Therapeutics

Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.

Ernexa Therapeutics Inc

Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) has outperformed the market over the past 10 years by 9.53% on an annualized basis producing an average annual return of 20.45%. Currently, Wix.com has a market capitalization of $8.82 billion. 
Buying $1000 In WIX: If an investor had bought $1000 of WIX stock 10 years ago, it would be worth $6,440.47 today based on a price of $158.50 for WIX at the time of writing.
<h3>Wix.com's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750282223_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250618-1478499/1478499_ussteel-x4.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250618-1478499/1478499_ussteel-x4.pdf</a>

General

APi Group Set to Join S&P MidCap 400; Will Replace United States Steel Corp Effective Prior To The Opening Of Trading On Tuesday

<a href="https://www.nytimes.com/live/2025/06/18/world/israel-iran-trump">https://www.nytimes.com/live/2025/06/18/world/israel-iran-trump</a>

Politics

iShares MSCI Israel Capped Investable Market Index Fund

'Iran is open to talks with the U.S., a senior diplomat says, even as the supreme leader rejects the idea.'- New York Times

Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) has outperformed the market over the past 10 years by 36.54% on an annualized basis producing an average annual return of 47.45%. Currently, Advanced Micro Devices has a market capitalization of $205.74 billion. 
Buying $100 In AMD: If an investor had bought $100 of AMD stock 10 years ago, it would be worth $4,839.31 today based on a price of $126.89 for AMD at the time of writing.
<h3>Advanced Micro Devices's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750281345_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

<a href="https://www.wsj.com/livecoverage/iran-israel-conflict-news">https://www.wsj.com/livecoverage/iran-israel-conflict-news</a>

Macro Notification

'Trump Privately Approved Attack Plans For Iran But Has Withheld Final Order'- WSJ

<a href="https://www.reuters.com/business/media-telecom/putin-says-he-is-ready-talk-with-germanys-merz-2025-06-18/">https://www.reuters.com/business/media-telecom/putin-says-he-is-ready-talk-with-germanys-merz-2025-06-18/</a>

'Putin says he is ready to talk with Germany's Merz'- Reuters

In January 2025, following the unsolicited approach from Orbic to acquire Sonim, the Sonim Board formed a Special Committee to explore and evaluate a range of strategic alternatives to maximize stockholder value. Both strategically and tactically, the Special Committee has already found a potentially better alternative for Sonim stockholders to a transaction with Orbic. The Company provided further details in a letter to stockholders, highlights include:
<ul>
<li>Sale of Assets to Social Mobile: As announced on June 2, 2025, Sonim and Social Mobile have signed a Letter of Intent intended to lead to a definitive agreement under which Social Mobile will acquire substantially all of Sonim's operating assets for up to $20 million, including up to $5 million in earn-out consideration.</li>
<li>Reverse Takeover Transaction: Sonim intends to enter a definitive agreement with a prospective reverse takeover candidate in addition to the transaction with Social Mobile. The company is targeting a $15 million estimated value for Sonim. Together with the Social Mobile transaction, the aggregate potential value exceeds the value of Orbic's purported offer.</li>
<li>Orbic's Lack of Engagement: Despite the Special Committee's efforts to meaningfully engage, Orbic has demonstrated nothing but strategic inconsistency, abrupt tactical shifts, and adversarial behavior.</li>
<li>Orbic's Financial Distress: Orbic and its affiliates have more than $22.5 million in judgments against them, over ten lawsuits in the past decade, including disputes with customers, suppliers, employees, and business partners.</li>
<li>Orbic's Campaign and Illusory Proposal is an Attempt to Derail Strategic Alternatives Process: Sonim believes that Orbic's proxy contest is not about governance or performance—it is a continuation of Orbic's coercive strategy aimed at derailing Sonim's strategic alternatives process and an attempt to seize control of the Board and Company without paying a premium to all Sonim stockholders.</li>
</ul>

SONM

Sonim Technologies Announces Update on Strategic Alternatives Initiatives

<h3>Gainers</h3>
<ul>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares rose 6.2% to $2.74 during Wednesday's after-market session. The company's market cap stands at $9.3 million. </li>
<li>NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) stock increased by 5.16% to $1.63. The market value of their outstanding shares is at $91.6 million. </li>
<li>Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) stock moved upwards by 4.99% to $40.36. The company's market cap stands at $1.4 billion. </li>
<li>PubMatic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) stock rose 4.97% to $11.61. The market value of their outstanding shares is at $563.4 million. </li>
<li>PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) shares moved upwards by 4.43% to $2.12. The company's market cap stands at $96.5 million. </li>
<li>LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) stock rose 3.81% to $0.8. The market value of their outstanding shares is at $76.5 million. As per the news, the Q4 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>PodcastOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODC#NASDAQ">PODC</a>) shares declined by 4.9% to $1.93 during Wednesday's after-market session. The company's market cap stands at $48.0 million. The company's, Q4 earnings came out today. </li>
<li>Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) shares fell 4.47% to $1.71. The company's market cap stands at $89.7 million. </li>
<li>Mega Matrix (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MPU#AMEX">MPU</a>) shares decreased by 4.45% to $0.85. The company's market cap stands at $34.6 million. </li>
<li>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) shares decreased by 3.6% to $5.36. The market value of their outstanding shares is at $1.0 billion. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) shares declined by 3.4% to $0.56. The market value of their outstanding shares is at $15.8 million. </li>
<li>Stran &amp; Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) shares declined by 3.38% to $1.43. The company's market cap stands at $26.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEHL

CDLX

LILA

NIPG

PODC

PSQH

PUBM

SPHR

SWAG

TNMG

12 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock moved upwards by 9.6% to $2.63 during Wednesday's after-market session. The market value of their outstanding shares is at $6.9 million. </li>
<li>Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) shares increased by 8.93% to $3.17. The market value of their outstanding shares is at $137.0 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock rose 8.82% to $1.48. The market value of their outstanding shares is at $77.1 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock rose 7.38% to $0.71. The company's market cap stands at $36.7 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock moved upwards by 7.37% to $0.74. The company's market cap stands at $96.5 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) stock increased by 6.96% to $4.76. The market value of their outstanding shares is at $20.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock declined by 15.3% to $6.79 during Wednesday's after-market session. The company's market cap stands at $40.4 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock fell 10.59% to $0.76. The market value of their outstanding shares is at $2.0 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares decreased by 9.58% to $5.38. The market value of their outstanding shares is at $5.9 million. </li>
<li>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) stock declined by 6.22% to $0.34. The market value of their outstanding shares is at $7.9 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock declined by 5.85% to $3.41. The market value of their outstanding shares is at $48.9 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock declined by 5.42% to $2.62. The market value of their outstanding shares is at $94.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

ATRA

CING

IMRX

KYTX

LIXT

MODV

PPBT

PROK

QNCX

TSBX

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock moved upwards by 6.7% to $1.59 during Wednesday's after-market session. The market value of their outstanding shares is at $17.4 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares rose 5.17% to $0.06. The market value of their outstanding shares is at $1.9 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares rose 4.8% to $2.39. The company's market cap stands at $74.9 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock rose 4.66% to $0.42. The company's market cap stands at $60.4 million. </li>
<li>United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) shares rose 4.5% to $1.62. The company's market cap stands at $14.9 million. </li>
<li>Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) shares moved upwards by 4.5% to $0.63. The market value of their outstanding shares is at $47.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Armlogi Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOC#NASDAQ">BTOC</a>) shares decreased by 9.6% to $1.5 during Wednesday's after-market session. The market value of their outstanding shares is at $63.1 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock fell 9.52% to $0.32. The company's market cap stands at $4.0 million. </li>
<li>CDT Envirn Tech Inv Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) shares fell 8.17% to $0.9. The market value of their outstanding shares is at $11.0 million. </li>
<li>C3is (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISS#NASDAQ">CISS</a>) stock fell 7.43% to $3.24. The company's market cap stands at $2.2 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock declined by 7.01% to $0.6. The market value of their outstanding shares is at $10.7 million. </li>
<li>T1 Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TE#NYSE">TE</a>) shares decreased by 6.02% to $1.38. The market value of their outstanding shares is at $215.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTOC

CDTG

CISS

HKPD

HOVR

ILAG

SCWO

UGRO

USEA

WLGS

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock rose 16.6% to $21.93 during Wednesday's after-market session. The market value of their outstanding shares is at $404.9 million. The company's, Q1 earnings came out today. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) stock rose 7.84% to $0.23. The company's market cap stands at $10.4 million. </li>
<li>Maris Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEK#NASDAQ">MTEK</a>) stock increased by 7.29% to $3.09. The market value of their outstanding shares is at $24.3 million. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) stock moved upwards by 6.34% to $0.44. The market value of their outstanding shares is at $8.7 million. </li>
<li>Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) shares increased by 6.27% to $2.54. The company's market cap stands at $152.3 million. </li>
<li>Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) stock moved upwards by 4.33% to $2.65. The market value of their outstanding shares is at $103.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock decreased by 15.2% to $0.13 during Wednesday's after-market session. The company's market cap stands at $4.8 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares declined by 14.73% to $0.35. The company's market cap stands at $9.8 million. </li>
<li>Verb Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) shares fell 10.61% to $5.9. The market value of their outstanding shares is at $8.3 million. </li>
<li>Zenvia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) shares decreased by 7.61% to $1.7. The company's market cap stands at $89.1 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) stock fell 6.67% to $2.8. The company's market cap stands at $20.5 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) stock decreased by 5.66% to $0.84. The company's market cap stands at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMBM

GRRR

LDTC

LTRX

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MINM

MTEK

SMSI

VERB

ZENV

ZEPP

12 Information Technology Stocks Moving In Wednesday's After-Market Session

<a href="https://www.theinformation.com/articles/meta-talks-hire-former-github-ceo-nat-friedman-daniel-gross-join-ai-efforts">https://www.theinformation.com/articles/meta-talks-hire-former-github-ceo-nat-friedman-daniel-gross-join-ai-efforts</a>

'Meta in Talks to Hire Former GitHub CEO Nat Friedman, Daniel Gross to Join AI Efforts'- The Information

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 1.13% on an annualized basis producing an average annual return of 12.04%. Currently, HealthEquity has a market capitalization of $8.84 billion. 
Buying $100 In HQY: If an investor had bought $100 of HQY stock 10 years ago, it would be worth $315.69 today based on a price of $102.00 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750280431_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today

Looking into the current session, Clearwater Analytics Hldg Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) shares are trading at $21.80, after a 1.04% drop. Over the past month, the stock decreased by 2.85%, but over the past year, it actually went up by 17.46%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1750280418_0.png" alt="Past Year Chart" />

<h3>Clearwater Analytics Hldg P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Clearwater Analytics Hldg has a lower P/E than the aggregate P/E of 164.32 of the Software industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750280418_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

CWAN

P/E Ratio Insights for Clearwater Analytics Hldg

Gorilla Technology Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) shares are surging in Wednesday&#8217;s after-hours session after the company reported financial results for<a href="https://www.benzinga.com/pressreleases/25/06/46006146/gorilla-technology-reports-first-quarter-2025-profitability-global-execution-and-momentum-drive-109"> the first quarter</a>.
What Happened: Gorilla Technology reports first-quarter revenue of $18.26 million, up 109% year-over-year, driven by several global agreements. 
The company reported first-quarter adjusted earnings of 23 cents, improved from a loss of $1.47 per share in the prior year&#8217;s quarter, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Gorilla Technology said its pipeline is now in excess of $5 billion, &#8220;consisting of qualified leads where we have determined that there is a will and a budget to move forward and that we can close a deal within the next 12 months.&#8221;
The company ended the quarter with $33.8 million in cash, which includes $20.8 million in restricted cash. 
&#8220;Gorilla has launched into 2025 with power, precision and clarity of purpose. This quarter is not just a performance milestone — it is proof of trajectory,&#8221; said Jay Chandan, chairman and CEO of Gorilla Technology.
&#8220;Revenue is up, margins are firm and profitability is no longer aspirational, it is embedded. With momentum on our side, we are no longer just building our pipeline, we are&nbsp;converting at scale, compounding growth across borders and deepening trust with some of the world's most ambitious partners.&#8221;
Gorilla Technology&#8217;s management team is currently discussing the quarter on a call with investors and analysts that kicked off at 4:30 p.m. ET.
GRRR Price Action: <a href="http://benzinga.com/quote/grrr">Gorilla Technology shares</a> were up 13.13% after-hours, trading at $21.30 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46004391/my-favorite-magnificent-7-trade-for-this-week">My Favorite Magnificent 7 Trade For This Week</a></li>
</ul>
Photo: Billion Photos/Shutterstock.

After-Hours Center

Tech

Gorilla Technology Stock Surges On Q1 Earnings As Momentum Builds

Roundhill Investments launched five new <a href="https://www.benzinga.com/etfs">WeeklyPay ETFs</a>, each aiming to deliver weekly dividends without sacrificing upside or using options.
The new additions include:
<ul class="wp-block-list">
<li>Roundhill AMZN WeeklyPay ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/AMZW#BATS">AMZW</a>), following Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), </li>
<li>Roundhill BRKB WeeklyPay ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BRKW#BATS">BRKW</a>), following Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), </li>
<li>Roundhill HOOD WeeklyPay ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/HOOW#BATS">HOOW</a>), following Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)</li>
<li>Roundhill META WeeklyPay ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/METW#BATS">METW</a>), following Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) </li>
<li>Roundhill NFLX WeeklyPay ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/NFLW#BATS">NFLW</a>), following Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</li>
</ul>
These launches bring the WeeklyPay family to 10 ETFs. Each fund aims to capture 120% of the aggregate return of its underlying security each calendar week, as well as a regular distribution.
That&#8217;s a clear divergence from the way most single-stock income ETFs operate, usually through selling covered calls, which exchange upside potential for option premiums. And with more than $15 billion flowing into such a strategy, the company obviously believes there is room for disruption.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/06/45982963/global-xs-new-gxig-etf-offers-ai-powered-bond-etf-for-smarter-fixed-income-investing">Global X&#8217;s New GXIG ETF Offers AI-Powered Bond ETF For Smarter Fixed Income Investing</a>
<h2 class="wp-block-heading">A Different Kind Of Income ETF</h2>
Instead of depending on derivatives, Roundhill&#8217;s WeeklyPay ETFs employ leverage to enhance returns, aiming at 1.2x the performance of the underlying stock on a weekly basis. That multiplier, naturally, involves risk, particularly in downward environments, but it also avoids having investors forego gains in a bull market, as with covered call strategies.
The money also makes weekly payments, which might be enticing for income-oriented investors tired of the slow dribble of dividends.
<h2 class="wp-block-heading">From Tech Giants To Meme Stocks</h2>
Roundhill&#8217;s current roster already boasts single-stock ETFs tied to such names as Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and Palantir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>). But the company isn&#8217;t yet done.
It has applied for additional WeeklyPay ETFs tracking an eclectic roster: from blue chips such as Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), to semicon-weighty names such as AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), to speculative darlings such as Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>), DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), and MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>).
The message is plain: Roundhill is looking to track the entire gamut of investor demand—tech, momentum, income, and high-risk stocks—all under one umbrella.
<h2 class="wp-block-heading">What To Watch</h2>
While the structure has upside potential, it&#8217;s not without its cautionary tales. Leveraged exposure, even at a 1.2x rate, amplifies gains and losses as much as it amplifies the underlying. And while the absence of options sidesteps issues of premium decay and call-away risk, investors should still look at how distributions are made and what level of volatility to anticipate.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46001274/alibabas-high-speed-comeback-the-ai-commerce-cocktail-lifting-etf-hopes?utm_campaign=Watchlist&amp;utm_source=Benzinga&amp;utm_medium=Email">Alibaba&#8217;s High-Speed Comeback: The AI-Commerce Cocktail Lifting ETF Hopes</a></li>
</ul>
Image: Shutterstock

New ETFs

ETFs

AAPL

AMZN

AMZW

ASML

Roundhill ETF Trust Roundhill BRKB WeeklyPay ETF

BRKW

DKNG

GOOGL

HOOD

Roundhill ETF Trust Roundhill HOOD WeeklyPay ETF

HOOW

Roundhill ETF Trust Roundhill META WeeklyPay ETF

METW

MSFT

MSTR

Roundhill ETF Trust Roundhill NFLX WeeklyPay ETF

NFLW

NFLX

NVDA

PLTR

RDDT

TSLA

Roundhill's New ETFs Offer Weekly Income From Amazon, Meta, Netflix, And More

Top banker Jamie Dimon is calling for a sweeping transformation of the U.S. education system, warning that schools must evolve to meet the demands of <a href="https://www.benzinga.com/topic/employment">a rapidly changing workforce</a>.
What Happened: The JPMorgan Chase &amp; Co CEO, in an appearance at the Business Roundtable&#8217;s CEO Workforce Forum, <a href="https://www.businessinsider.com/jamie-dimon-skills-shortage-schools-business-roundtable-2025-6">emphasized</a> the need for schools to integrate coding, cyber security and financial management into their curricula.
Dimon said that aligning educational programs with industry needs will better equip students to secure jobs in these high-demand fields. 
Dimon, who is also a board member of the New York Jobs CEO Council, <a href="https://www.businessinsider.com/jamie-dimon-skills-shortage-schools-business-roundtable-2025-6">highlighted</a> how some educational institutions are collaborating with the private sector to create programs that enhance job readiness.
See Also: <a href="https://benzinga.com/markets/macro-economic-events/25/06/45988656/elon-musk-warns-us-faces-de-facto-bankruptcy-if-37-trillion-debt-not-tackled-peter-" target="_blank" rel="noreferrer noopener">Elon Musk Warns US Faces &#8216;De Facto&#8217; Bankruptcy If $37 Trillion Debt Not Tackled, Peter Schiff Says, &#8216;We Are Already Bankrupt&#8217;</a>
Why It Matters: <a href="https://www.benzinga.com/topic/jamie-dimon">Dimon</a> argues that businesses must take an active role in bridging the skills gap, rather than relying on government initiatives.
This approach could help mitigate the impact of technological advancements on employment and ensure a steady supply of skilled workers in critical areas.
Dimon&#8217;s sentiment comes as young graduates enter a workforce where automation and AI are rapidly displacing entry-level positions.
Chris Hyams, the CEO of popular job-search platform Indeed, recently warned that &#8220;for about two-thirds of all jobs, 50% or more of those skills are things that today&#8217;s generative AI can do reasonably well, or very well.&#8221;
Citing a study, which dissected roughly two million postings skill by skill, Hyams&#8217; blunt takeaway is that &#8220;pretty much every job is going to change if <a href="https://www.benzinga.com/25/05/45511651/ai-wont-steal-your-paycheck-yet-two-thirds-of-all-jobs-have-half-their-skills-up-for-grabs-says-indeed-ceo-chris-hyams">it&#8217;s not changing already</a>.&#8221;
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/news/legal/25/06/45990612/trump-administration-illegally-slashed-over-1-billion-in-nih-grants-mostly-linked-to-dei-federal-judge" target="_blank" rel="noreferrer noopener">Trump Administration Illegally Slashed Over $1 Billion In NIH Grants Mostly Linked To DEI, Federal Judge Rules</a></li>
</ul>
Image: Shutterstock

Jamie Dimon Sounds Alarm On Skills Gap, Calls For Overhaul Of US Education System

Offerings

LODE

Comstock Files For Shelf Of Up To 2.2M Shares Of Common Stock By Selling Stockholders

Aurora Cannabis Denies News Of New Zealand-Based MedLeaf Therapeutics Acquisition

Editor&#8217;s note: This article has been updated to reflect the accurate percentage of the German population participating in the medical cannabis market. 
Shares of Aurora Cannabis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) fell roughly 20% on Wednesday following the company's fiscal <a href="https://www.benzinga.com/cannabis/25/06/45997534/canadian-medical-marijuana-firm-aurora-cannabis-expects-weak-demand-in-international-market">Q4 and full-year 2025 earnings report</a>, even after reporting record-high medical cannabis revenue, adjusted EBITDA and positive free cash flow.
But CEO Miguel Martin isn't sweating the reaction.
"It was record earnings, record EBITDA, record free cash flow for the year," Martin told <a href="https://www.benzinga.com/cannabis">Benzinga</a>. "Given the totality of the year and the quarter we put forth, I think it's a bit of an overreaction, but I understand it. I know people are sensitive."
<h3 class="wp-block-heading">A Temporary Dip, Not a Trend</h3>
The company forecasted a short-term dip in international cannabis sales for the current quarter. Some investors seized on that detail, sending the stock lower.
"All [the guidance] said was that Q1 was going to be a little bit less in revenue and EBITDA connected to international cannabis than Q4," Martin explained. "We expect it to come back in Q2. We expect to be free cash flow positive for Q1 and for the year."
That Q1 softness, he added, is tied to short-term challenges in two of Aurora's core international markets.
"In Poland, it's about the regulatory process for patients to get prescriptions. In the UK, we had a little bit of timing as we brought on some new distributors," Martin said. &#8220;We think both will normalize, and neither should have an impact outside of Q1.&#8221;
<h3 class="wp-block-heading">Focused On Medical, Not Chasing Recreational</h3>
Medical cannabis accounted for 75% of Aurora's Q4 revenue and nearly 90% of its gross profit.
"All of the profitability comes from medical cannabis and our investment in Bevo," Martin said, referring to the company's non-cannabis plant propagation business. "Our expertise and history is in medical cannabis."
Aurora still operates in Canada's adult-use market, but Martin made it clear that the segment is a small piece of the puzzle.
"Its purpose is to learn and innovate and get insights. We've right-sized it for us as we focus on profitability and growth. Right now, there are no plans to phase it out."
Aurora also <a href="https://www.benzinga.com/markets/cannabis/24/09/40970562/nasdaq-listed-aurora-cannabis-breaks-up-with-uruguay-its-not-you-its-the-market">exited its Uruguay operations last year</a>. Martin said the decision came down to commercial reality, not regulatory disappointment.
Also read: <a href="https://www.benzinga.com/markets/cannabis/25/05/45410084/legal-cannabis-10-years-later-real-data-from-the-first-country-to-do-it">Legal Cannabis, 10 Years Later: Real Data From The First Country To Do It</a>
"We thought there'd be opportunities to produce in Uruguay and then sell in Brazil. Unfortunately, with THC, it became challenging to certify and sell those products. It just didn't work out for us."
<h3 class="wp-block-heading">Growing International Markets</h3>
More than 60% of Aurora's medical cannabis revenue now comes from outside Canada. Martin said that global growth will continue in familiar markets.
"Germany has roughly 0.4% of the adult population in the medical cannabis system. Canada's got 1%. So there's plenty of upside there," he told Benzinga. "In the next 12 months, it's going to be focused on increasing our market share in those locations."
While Aurora does operate a GMP-certified facility in Germany, Martin said most production remains centered in Canada.
"Because these are pharmaceutical products, we believe that the vast majority of our products sold globally will be produced in Canada."
<h3 class="wp-block-heading">The Bevo Bet</h3>
Aurora's Bevo Farms unit posted 32% year-over-year growth, and Martin highlighted a new revenue stream: orchids.
"We think Bevo will continue to be profitable and support what we're trying to do. It's a wonderful adjacency for us, even if it's not in the cannabis business," he said.
Martin emphasized that profitability—not brand synergy—is what drives investment decisions.
"If it wasn't profitable or accretive to our financials, we wouldn't have done it."
<h3 class="wp-block-heading">The Real Risk</h3>
"The biggest risk is perception," Martin said. "Five years ago, people had big expectations for cannabis and they didn't materialize. Now it's hard for people to differentiate companies. Today, there are only a handful of companies that are free cash flow positive, have no debt and have a real strong growth trajectory, and we're one of them."
He also pointed to timing and policy volatility as ongoing challenges.
"We&#8217;re not seeing markets close or places legalize and then undo that. We&#8217;re talking about big economies here. Medical cannabis is profitable and it&#8217;s growing. And if you believe in it, Aurora should be a pick," Martin concluded.
Photo: Shutterstock

Cannabis

Earnings

Latin America

Eurozone

Exclusives

Interview

EXCLUSIVE: Medical Cannabis Is Growing And Profitable, Says Aurora CEO — Investors Are Just Missing The Story

Health Care

Press Releases

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Management

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease

Ernexa Therapeutics Closes New Funding Round

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Comments

Ernexa Therapeutics

Noticias

Últimas noticias sobre Ernexa Therapeutics (NASDAQ:ERNA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL